Systemic lupus erythematosus (SLE) is a complex autoimmune disease that follows an unpredictable disease course and affects multiple organs and tissues. We performed an integrated, multi-cohort analysis of 7,471 transcriptomic profiles from 40 independent studies to identify robust gene expression changes associated with SLE. We identified a 93-gene signature (SLE MetaSignature) that is differentially expressed in the blood of SLE patients compared to healthy volunteers; distinguishes SLE from other autoimmune, inflammatory, and infectious diseases; and persists across diverse tissues and cell types. The SLE MetaSignature correlated significantly with disease activity and other clinical measures of inflammation. We prospectively validated the SLE MetaSignature in an independent cohort of pediatric SLE patients using a microfluidic RT-qPCR array. We found that 14 of the 93 genes in the SLE MetaSignature were independent of interferon-induced and neutrophil-related transcriptional profiles that have previously been associated with SLE. Pathway analysis revealed dysregulation associated with nucleic acid biosynthesis and immunometabolism in SLE. We further refined a neutropoeisis signature and identified under-appreciated transcripts related to immune cells and oxidative stress. Our multi-cohort, transcriptomic analysis has uncovered under-appreciated genes and pathways associated with SLE pathogenesis, with the potential to advance clinical diagnosis, biomarker development, and targeted therapeutics for SLE.
Introduction
Systemic lupus erythematosus (SLE) is a complex, heterogeneous, chronic autoimmune disease that can affect multiple organs and tissues, including the skin, kidneys, joints, lungs, blood, and central nervous system. SLE follows an unpredictable disease course, punctuated by periods of flare and remission (1) . High titer, class-switched antibodies that bind to nuclear antigens including dsDNA, ribonucleoprotein (RNP), Smith, SSA (Ro), and SSB (La), are used in the diagnosis and monitoring of SLE, and are thought to be pathogenic. The heterogeneity of SLE makes it challenging for clinicians to manage. Identification of robust molecular changes associated with SLE, despite the patient heterogeneity, will likely improve our understanding and management of SLE.
A number of gene expression studies have shed light on the molecular pathogenesis of SLE. For example, microarray analyses of blood cells derived from SLE patients have shown that the interferon (IFN) pathway is dysregulated in a subset of individuals who have more active and severe disease (2) (3) (4) (5) . Increases in IFN-related genes have also been observed in subsets of patients with other diseases, including systemic sclerosis (SSc), dermatomyositis (DM), polymyositis (PM), primary Sjögren's syndrome (SS), and rheumatoid arthritis (RA), although levels of IFN-inducible gene products were typically highest in SLE (6) (7) (8) (9) (10) . A review of the biomedical literature identified IFN and neutrophils as a major focus of recent SLE research, with approximately 150 and 40 references per year, respectively. In addition to the IFN signature, up-regulation of transcripts associated with granulopoiesis and plasmablasts were observed in individuals who have SLE and found to be associated with disease activity (3, 5) . McKinney et al. used gene expression analysis of purified immune cell populations to identify a transcriptional signature in CD8 T cells that was associated with increased likelihood of SLE disease flare (11) . They went on to identify an exhaustion signature, associated with decreased risk of flare, in CD8 T cells from individuals who have SLE (12) . However, the majority of these studies have been limited by small sample sizes, low levels of clinical and geographic heterogeneity, potential artifacts related to use of a single experimental gene array platform, and lack of external validation. A more robust approach is needed to interrogate the molecular signatures that underlie the highly variable presentation and course of SLE.
We have previously described a multi-cohort analysis framework (MetaIntegrator) to identify robust disease signatures, and repeatedly demonstrated its applications for discovering novel diagnostics, prognostics and drug targets, and drug repurposing, which leverages the biological and technical heterogeneity present in the large amounts of publicly-available gene expression data across a broad spectrum of conditions including infections, organ transplant, vaccination, cancer, and autoimmune diseases (13) (14) (15) . MetaIntegrator is based on a random-effects meta-analysis, drawing statistical power from the integration of many diverse datasets (14) . By computing effect sizes for each dataset independently, MetaIntegrator embraces heterogeneity and avoids the limitations of batch effect correction. We have demonstrated application of this framework across a broad spectrum of diseases including cancer (16, 17) , solid organ transplant (13) , sepsis (18) , viral infection (19) , tuberculosis (20) , neurodegenerative diseases (21) , vaccination (22) , and systemic sclerosis (23) . Here, we applied the framework to analyze 40 publicly-available whole transcriptome profile datasets containing 7,471 samples from SLE patients, individuals with other autoimmune diseases or infections, and healthy volunteers. Together, these datasets represented real-world diversity because of both (i) the biological heterogeneity, as the samples were collected from multiple tissue and cell types (e.g. blood, skin, and kidney) at 17 centers across five countries; and (ii) the technical heterogeneity, as data were generated using diverse microarray platforms (e.g. Affymetrix arrays, Illumina beadchips, and Hitachisoft chips). Our analysis identified a robust SLE MetaSignature that (i) distinguishes SLE from other autoimmune and inflammatory diseases; (ii) is present in multiple affected tissues and immune cell subsets; (iii) is independent of age; and (iv) is correlated with disease activity. We validated the SLE MetaSignature using additional independent publicly-available transcript datasets. We then devised a custom, microfluidic RT-qPCR assay to analyze RNA transcripts in blood derived from a prospective, independent pediatric SLE (pSLE) cohort. Pathway analysis identified novel dysregulated pathways in SLE, including those related to nucleotide biosynthesis and metabolism. Importantly, we identified a non-IFN component of the SLE MetaSignature that correlated more positively with disease activity measures than the IFN-related genes. Finally, our results discovered 14 "non-IFN, nonneutrophil" genes as under-appreciated targets for biomarker and therapeutic development.
Results

Identification of the SLE MetaSignature
To perform a comprehensive, unbiased study of the molecular changes underlying SLE, we identified and downloaded gene expression data from all publicly-available human SLE datasets in Gene Expression Omnibus (24) . In total, we identified 40 datasets from 17 centers in 5 countries comprised of 7,471 samples derived from whole blood, PBMCs, kidney, skin, synovium, B cells, T cells, monocytes, neutrophils, and endothelial progenitor cells (Figure 1 , Tables 1-3 ). We randomly selected 6 datasets consisting of 370 whole blood and PBMC samples as "Discovery" datasets, based on our previous finding that 5 datasets with 250-300 samples are sufficient to find a robust disease gene signature using our multi-cohort analysis framework (14) . We divided the remaining 34 datasets into "Validation" (2,407 samples in 8 datasets) and "Extended Validation" datasets (4,694 samples in 26 datasets). Discovery and Validation datasets were required to include PBMC or whole blood samples from healthy controls and SLE patients. Extended Validation datasets included samples from other tissues or cell types, comparisons between SLE and other diseases, and longitudinal SLE samples.
We identified 93 significantly differentially regulated genes (82 up-regulated and 11 downregulated; Table S1 ) with a false discovery rate (FDR) ≤ 5% and an absolute effect size ≥ 1 compared to healthy volunteers in the Discovery datasets ( Figure 2A , Table S1 ). We defined these 93 genes as the "SLE MetaSignature." In the Validation datasets, 73 of these 93 SLE MetaSignature genes met the same filtering criteria (|ES| ≥ 1 and FDR ≤ 5%) and effect sizes for all 93 genes exhibited the same directionality as in the Discovery datasets ( Figure 2B , Figure S1 ). Of the 20 SLE MetaSignature genes that did not meet the filtering criteria, 18 were statistically significant (FDR ≤ 5%), but had an effect size less than 1 (median effect size 0.78). but had an effect size less than 1 (median effect size 0.78). In the Extended Validation datasets, which included data from diverse sample types and other diseases, the SLE MetaSignature gene effect sizes were consistent with the Discovery dataset ( Figure 2C ). Regardless of the genetic background of the patients, technical variation, tissue, and cell type, the genes comprising the SLE MetaSignature were all differentially expressed (Figure 2A -C), demonstrating the robustness of the SLE MetaSignature.
We defined an "SLE MetaScore" for each sample using the 93-gene signature (see Methods). In the Discovery datasets, the SLE MetaScore distinguished SLE patient samples from healthy samples with a summary area under the receiver operating characteristic curve (AUROC) of 0.95 (95% confidence interval (CI) 0.83-0.99) ( Figure 2D ). The SLE MetaScore distinguished samples from SLE patients and healthy volunteers with high accuracy in the 8 Validation datasets (summary AUROC=0.94, 95% CI = 0.89-0.97) ( Figure 2E ), further demonstrating the robustness of the SLE MetaSignature.
Of the 93 genes in the SLE MetaSignature, 46 had been previously associated with SLE (2, 3, 5, 25) . To the best of our knowledge, the remaining 47 genes have not previously been associated with SLE. We performed pathway analysis of the SLE MetaSignature using Differential Expression Analysis for Pathways (DEAP) (26) to identify biological processes that are dysregulated in SLE. DEAP takes advantage of the meta-analysis effect sizes for all genes (not just those in the SLE MetaSignature) and pathway topology to identify patterns of differential expression that are consistent with known biological pathways. By taking advantage of effect sizes of all genes, DEAP significantly improves power compared to gene list based approaches (26). Further, DEAP specifies genes involved in the most differentially expressed subpathway. As input for DEAP, we used study level effect sizes from the Discovery and Validation datasets (26) . Table S2 summarizes pathways that were differentially expressed at a false discovery rate (FDR) £ 0.10 based on 5,000 random rotations of the data. In addition to the expected inflammatory pathways (e.g. IFNg signaling pathway, chemokine/cytokine-mediated signaling pathway, and interleukin signaling pathway), our analysis identified several highly significant, unexpected pathways (salvage pyrimidine deoxyribonucleotides, formyltetrahydrofolate biosynthesis, and salvage pyrimidine ribonucleotides) related to nucleic acid metabolism. Thus, pathway analysis of the SLE MetaSignature provided insights into the biological mechanisms underlying SLE.
SLE MetaScore distinguishes SLE from other autoimmune, inflammatory, and infectious diseases
We compared SLE MetaScores across inflammatory conditions, including other autoimmune and infectious diseases to explore its specificity to SLE. We found that adult SLE (aSLE) and pediatric SLE (pSLE) patients had significantly higher SLE MetaScores than individuals with staphylococcal infection, streptococcal pharyngitis, Still's disease (systemic onset juvenile idiopathic arthritis, sJIA), RA, pyogenic pyoderma gangrenosum and acne (PAPA), B cell deficiency, diabetes, human immunodeficiency virus infection, and liver transplant acute rejection in whole blood and PBMC samples across multiple independent datasets ( Figure 3A -B and Figure S2A -B). In concordance with the previously reported increased severity of disease observed in pediatric SLE patients compared to adults (27) , we found that pediatric SLE patients had significantly higher SLE MetaScores compared to adult SLE patients ( Figure 3B ). Taken together, these results demonstrate that, both in adult and pediatric populations, the SLE MetaScore is highly specific to SLE compared to other autoimmune, inflammatory, and infectious diseases.
The SLE MetaScore is systemically higher across tissues in SLE patients
SLE is a systemic autoimmune disease that affects multiple tissues and organs. Therefore, we explored whether the SLE MetaScore is persistent in tissues other than whole blood and PBMCs in SLE patients. SLE MetaScores were higher in a dataset derived from glomeruli and tubulointerstitium of kidneys from individuals with SLE compared with pre-transplant living donors ( Figure 3C and Figure S3A ). SLE MetaScores were higher in a dataset from synovial biopsies of SLE patients compared to those with microcrystalline arthritis (gout and pseudogout), osteoarthritis (OA), RA, or seronegative arthritis ( Figure 3D ). Finally, we found that a dataset derived from skin biopsies from individuals with discoid lupus erythematosus exhibited significantly higher SLE MetaScores than healthy volunteers and individuals with psoriasis, suggesting shared pathways between systemic and cutaneous lupus ( Figure  S3B ). Collectively, these results provide strong evidence that the SLE MetaScore is higher in multiple affected tissues in SLE in comparison to both healthy controls and other autoimmune diseases.
The SLE MetaScore is differentially expressed in diverse immune cell types
Multiple functional changes have been described in T cells of SLE patients, including upregulation of co-stimulatory molecules, hypomethylation, increased expression of key immune-related genes (28) , and aberrant signaling pathway activation downstream of TCR activation (29) . We found that the SLE MetaScore was significantly higher in multiple independent datasets from CD4+ T cells of SLE patients compared to healthy volunteers (Figures S4A-C) and RA patients ( Figure 3E ). Similarly, the SLE MetaScore was significantly increased in a dataset from CD8+ T cells of individuals with SLE, compared to healthy volunteers ( Figure S4D ).
Dysregulation of B cells is a hallmark of SLE, including autoantibody production, defective negative selection, and changes in the proportions of key B cell subpopulations (30, 31) . The SLE MetaScore was less robust in datasets from B cells than T cells, classifying SLE in some datasets ( Figure  3F and Figure S4E ) but not others ( Figure S4F -G). Finally, the SLE MetaScores in datasets from monocytes and neutrophils were not significantly different between SLE patients and healthy controls (data not shown).
The SLE MetaScore is positively correlated with disease activity and inflammation
The SLE Disease Activity Index (SLEDAI) is a standardized, albeit imperfect, measure of disease severity and activity. SLEDAI is based on the presence or absence of 24 features at the time of the visit, including arthritis, rash, fever, and increases in anti-DNA auto-antibodies. It is often used by clinicians to monitor disease activity in an individual SLE patient (3) . Five independent datasets that profiled PBMC or whole blood samples from SLE patients also reported SLEDAI scores. We observed a positive correlation between SLEDAI and the SLE MetaScore across each of the five datasets ( Figure 4A -B, Figure S5A -D). The median correlation across these studies (0.281) was significantly elevated compared to random gene sets (p < 0.01). The weakest SLEDAI correlation is observed in GSE27427, which contains only 18 samples and is derived from neutrophils. The positive correlation of SLEDAI with SLE MetaScore in the blood is notable, considering the SLE MetaSignature was identified without considering disease activity when selecting initial datasets for discovery. Further, we found that the SLE MetaScore correlated highly with individual clinical measures of systemic inflammation including erythrocyte sedimentation rate (ESR) ( Figure S5E ) (32) , and levels of complement C3 ( Figure 4C ) and C4 ( Figure S5F ).
Prospective validation of SLE MetaSignature in an independent pSLE cohort
We validated the SLE MetaSignature in an independent pediatric cohort by studying RNA transcripts in whole blood samples from healthy adult controls, and pediatric patients with SLE or JIA. We selected 33 genes from the SLE MetaSignature based on their significance and availability of validated probes for measuring expression using a microfluidic RT-qPCR array (Table S3 ). Thirty genes out of 33 were significantly differentially expressed in SLE samples compared to healthy adult controls and pediatric JIA patients (FDR < 5%, Table S3 ). Further, the SLE MetaScores based on these 33 genes in the pediatric SLE patients were significantly higher than healthy adult controls and pediatric JIA patients (p=3.7e-5 and 1.8e-6, respectively; Figure 5A ); distinguished pediatric SLE patients with high accuracy (AUROC=0.94); and were positively correlated with SLEDAI (Spearman correlation=0.307, p=0.045; Figure 5B ).
A subset of the SLE MetaSignature is not robustly induced by IFN
Dysregulation of the type I IFN pathway has been repeatedly observed in subsets of SLE patients with active disease, and is thought to be a critical mediator in disease pathology. Therefore, we explored the proportion of IFN-stimulated genes in the SLE MetaSignature. We analyzed 16 transcriptome datasets composed of 190 samples derived from primary human cells treated with type I IFN to identify a robust set of type I IFN-stimulated genes (Table S4) . Of the 93 genes in the SLE MetaSignature, 70 were significantly differentially expressed (effect size > 0.8) in primary cells stimulated by type I IFN ( Figure  6 , Table S1 ). The remaining 23 genes in the SLE MetaSignature had low effect sizes and high FDRs within the IFN-stimulated datasets ( Figure S6 ), suggesting that these 23 genes were not affected in cells exposed to type I IFN.
We separated the SLE MetaSignature into "IFN" and "non-IFN" SLE MetaSignatures, and computed score as before. Both scores distinguished SLE patients with equally high accuracy in the validation datasets (Table SE ). In four out of five datasets with SLEDAI disease severity measurements, the non-IFN SLE MetaSignature had a higher correlation with SLEDAI than the IFN SLE MetaSignature (Table SF) . Collectively, our analyses identified a clinically important, non-IFN component of the SLE MetaSignature.
The role of non-IFN MetaSignature genes in neutrophils
We used immunoStates to identify cell lineages that most highly express genes that comprise the SLE MetaSignature. We found that many of the non-IFN SLE MetaSignature genes were up-regulated in neutrophils (33) , consistent with prior literature implicating neutrophils in SLE (3, (34) (35) (36) (37) (38) . Low density granulocytes exhibit enhanced type I IFN production and NETosis, a form of neutrophil cell death implicated in SLE pathogenesis (39) in which DNA neutrophil extracellular traps (NETs) are extruded from activated neutrophils (36, 39) . We identified a transcript profiling dataset that compared low density granulocytes and neutrophils from SLE patients or healthy controls. We observed that the non-IFN SLE MetaSignature was prominently found in low density granulocytes from SLE patients, but not in neutrophils from SLE patients or healthy controls (35) ( Figure 7A ). We observed a strong correlation between neutrophil abundance and SLE MetaScore in both studies where quantitative neutrophil counts were available ( Figure S10 ). Collectively, these results suggest that the SLE MetaSignature genes related to neutrophils are the result of an expansion of the neutrophil compartment in SLE patients rather than an altered expression profile in SLE neutrophils.
To further explore the role of the non-IFN genes in neutrophils, we identified four publiclyavailable gene expression datasets with 84 samples that explored either NETosis or neutrophil development (Table S7 ). The non-IFN SLE MetaSignature was up-regulated in cell lines that were stimulated to induce both Nox-dependent and Nox-independent NETosis ( Figure 7B ). The non-IFN SLE MetaSignature progressively increases during intermediate stages of neutropoeisis ( Figure 7C and Figure S7A -B). Collectively, these results indicate that a significant proportion of the non-IFN SLE MetaSignature is related to transcriptional signatures of NETosis and neutropoeisis.
Identification of "under-appreciated, non-IFN, non-neutrophil" SLE MetaSignature genes
IFN stimulation and neutrophil involvement explained the differential expression of 79 of the 93 genes in the SLE MetaSignature ( Figure 8A , Table S1 ). The remaining 14 genes (termed "Under-appreciated SLE MetaSignature", ( Table 4 )) provided an opportunity to explore new disease mechanisms that underlie SLE. The Under-appreciated SLE MetaScore correlated more positively with disease activity measurements than the IFN SLE MetaScore in every blood derived dataset (Table S8 ). Interestingly, three members of the metallothionein family (MT1E, MT1F, and MT1HL1) were in the Underappreciated SLE MetaSignature. Metallothioneins play an important role in oxidative stress responses and the clearance of heavy metals. We identified two datasets in which human cell lines were exposed chronically to cadmium or acutely to zinc. The Under-appreciated SLE MetaSignature was significantly elevated in cells exposed to heavy metals when compared to the untreated cell lines (40) ( Figure 8B -C), providing a potential link between SLE and heavy metals, or with other environmental stimuli that induce oxidative stress. A cadre of the remaining 11 genes in the Under-appreciated SLE MetaSignature encode molecules with interesting functions related to immune cells, while the remainder of the genes have not been linked to SLE and have yet to be well characterized in the literature.
Discussion
Previous gene expression meta-analyses in SLE have been limited to few experiments, lacked external validation, or did not investigate the signature's specificity to SLE (41, 42) . Our method leverages biological and technical heterogeneity to identify a robust disease signature, and has been successful in diverse diseases that range from cancer to autoimmunity and infection (13, (16) (17) (18) (19) (20) (21) (22) (23) . We performed a multi-cohort gene expression analysis of over 7,000 samples from 40 datasets representing real-world biological heterogeneity (including genetic background, age, sex, treatment, tissue, cell type, and disease duration) and technical heterogeneity (including RNA isolation, microarray platform, sample preparation, and experimental protocol) to identify a persistent SLE MetaSignature. The robustness and reproducibility of the SLE MetaSignature demonstrate its generalizability to diverse patient populations not observed in traditional, single-cohort analyses (14) .
Beyond generalizability, the SLE MetaSignature was both specific to SLE and correlated with disease activity. Since the SLE MetaSignature distinguished SLE from other diseases such as diffuse or organ specific autoimmune diseases, inflammatory arthritides, and infectious diseases, the SLE MetaSignature identified SLE-specific disease processes instead of those that are generically dysregulated in other immune-mediated diseases. SLEDAI is the current standard for assessing severity of SLE disease activity although it is a qualitative, subjective, and difficult-to-reproduce measure (43) . Thus, the positive correlation between the SLE MetaScore and SLEDAI suggests that the SLE MetaScore is not only capturing disease activity, but also is quantitative and objective. Therefore, it could potentially serve as a metric of disease activity in future studies, or an exploratory outcome measure in future clinical trials. Because the SLE MetaScore includes both IFN and non-IFN genes, it expands upon the current best practices of using IFN focused gene expression to measure quantitative disease activity. Finally, to the best of our knowledge, this is the largest analysis of SLE performed to date that demonstrates that there is a transcriptional signature systemically expressed across different cell types and tissues from patients with SLE and is distinct from other autoimmune and infectious diseases. Our work has the potential to enable more precise molecular definition of SLE that is distinct from other autoimmune diseases.
The role of IFN in SLE has been important in improving the understanding of disease pathogenesis, leading to many publications defining the mechanisms of IFN in SLE (2-5) and several promising clinical trials testing anti-IFN treatments in SLE patients (44, 45) . To explore beyond this existing knowledge about the role of IFN in SLE, we specifically separated the SLE MetaSignature into genes related to IFN and genes that were independent of IFN based on a meta-analysis of 16 transcript profiling datasets from IFN-stimulated human cells. We found that the non-IFN SLE MetaSignature was equally accurate in identifying SLE patients. Notably, the non-IFN SLE MetaSignature had higher correlation with SLE disease activity compared to the IFN SLE MetaSignature. Prior studies have likely focused on the IFN-inducible signature due to the high effect sizes of these inflammatory genes.
Excluding highly differentially expressed IFN-inducible transcripts allowed us to focus on genes representative of the more nuanced biology underlying SLE.
Neutrophils also play a critical role in SLE pathogenesis. Low density granulocytes serve as the primary source of pro-inflammatory neutrophil extracellular traps (NETs) (3, (34) (35) (36) (37) (38) (39) . We found that the non-IFN SLE MetaSignature was most elevated in mature neutrophils, which contrasted with the more immature neutropoeisis signature observed in Bennett, et al. (3) . The non-IFN SLE MetaSignature was also elevated both in low density granulocytes and in response to NETosis-inducing stimulation. Overall, our work further refines the signature of neutropoeisis in SLE, and reinforces an important role for low density granulocytes and NETosis in SLE. Although B cells have an established role in SLE, the SLE MetaScore exhibited mixed results on available sorted B cell gene expression datasets. Due to limited availability of data, we cannot conclusively evaluate whether these challenges are the result of experimental conditions or a lack of signal in B cells.
One of the most exciting discoveries in the SLE MetaSignature is the identification of 14 genes that are unrelated to type I IFN or neutrophil-specific gene dysregulation, and are genes that by and large have not previously been implicated in SLE pathogenesis. These newly identified genes fall into categories that include genes with interesting known biology that are expressed in immune cells (e.g., KLRB1, GPR183 (also called EBI2), CD1C, and ELANE); genes involved in inflammation and cellular stress responses (MT1E, MT1F, and MT1HL1); and individual genes related to vitamin B12 metabolism (TCN2) and epidermal cellular integrity (DSC1).
The most striking group of genes that we identified were members of the metallothionein gene family (MT1E, MT1F, and MT1HL1). Metallothioneins are intracellular, cysteine-rich, metal-binding proteins involved in diverse intracellular functions that include clearance of heavy metals (cadmium, zinc, and copper) from cells, and maintenance of essential ion homeostasis (46, 47) . Metallothioneins normally bind zinc (48) , an important element and potent antioxidant that influences redox state, enzyme activity, gene transcription, energetic metabolism, cell cycle, cell migration, invasivity, apoptosis, and proliferation (49) . Both human cell line and animal studies have indicated a role for metallothioneins in protection against cadmium toxicity (50) (51) (52) (53) . Metallothioneins can be activated by a variety of stimuli, including metal ions, cytokines and growth factors, as well as oxidative stress and radiation (49, 54) . During oxidative stress, metallothioneins are up-regulated to protect the cells against cytotoxicity, radiation, and DNA damage (55) (56) (57) . Interestingly, metallothionein proteins are expressed at elevated levels in the kidneys of lupus nephritis patients (58) . We found that transcript profiles of human cell lines exposed acutely or chronically to heavy metals resembled the Under-appreciated SLE MetaSignature. We hypothesize that up-regulation of metallothioneins in SLE may be a protective response to elevated oxidative stress during chronic inflammatory responses and/or exposure to environmental sources of heavy metals (59) (60) (61) (62) . The importance of metallothioneins in SLE pathology is underscored by the observation that two additional family members (MT1A and MT2A) are induced by interferons and were identified in the 93 gene SLE MetaSignature.
The ELANE gene encodes neutrophil elastase (NE), a serine protease implicated in host defense and tissue injury. In addition to elastin, NE also hydrolyzes proteins within azurophil granules, extracellular matrix proteins, the outer membrane protein A (OmpA) of E. coli, and the virulence factors of other bacteria (63) . In contrast to the digestive serine proteases, NE has unusually high affinity for nucleic acids (64) . In naive neutrophils, NE is normally stored in azurophilic granules (65, 66) . Upon activation, NE translocates from azurophilic granules to the nucleus, where it partially degrades specific histones, thereby promoting chromatin decondensation and regulating the formation of NETs (67) . NE knockout mice are susceptible to bacterial and fungal infections (68, 69) . Mutations in ELANE can lead to cyclic and severe congenital neutropenia (70) . Furthermore, the NE enzyme may also play a role in various lung, bowel, and skin inflammatory diseases (71) . Dysregulation of ELANE in SLE was previously noted in a single cohort gene expression profile (72) . Although known as a neutrophilexpressed gene (hence its name), we did not identify neutrophil-specific dysregulation of ELANE in our analysis of SLE datasets, and rather than being classified under the neutrophil-related SLE MetaSignature genes, ELANE was instead classified as a "Under-appreciated SLE MetaSignature" gene. Unexpectedly, our further analysis of cell type expression of ELANE using immunoStates (33) indicated that ELANE is most differentially expressed in hematopoietic progenitor cells and basophils ( Figure S8 ). This suggests that novel functions for ELANE in other cells, in addition to neutrophils, may be involved in the pathophysiology of SLE.
DSC1 encodes a calcium-dependent glycoprotein in the desmocollin subgroup of the cadherin family. The desmocollins are critical adhesive proteins of the desmosome cell-cell junction linking epithelial cells, and are required for cell adhesion and desmosome formation. DSC1 is expressed in the upper epidermis of the skin (73) and has been implicated as an autoantigen for bullous skin disease (74, 75) , which is also frequently manifested in SLE patients (75) . Mice lacking DSC1 exhibit epidermal fragility accompanied by defects in epidermal barrier and differentiation (76) . Neonatal mice lacking desmocollin develop epidermal lesions, and older mice develop ulcerating lesions resembling chronic dermatitis. Based on the above observations, we speculate that the abnormally low levels of DSC1 in SLE patients lead to reduced adhesion and barrier maintenance of the upper epidermis, increasing the susceptibility to development of bullae and dermatitis.
KLRB1 (also known as CD161) encodes a C-type lectin-like receptor that is composed of a disulfide-linked homodimer of ∼40 kDa subunits, and is part of the natural killer gene complex (NKC) (77) . KLRB1 has been previously shown to be down-regulated in SLE (35, 78, 79) . This gene is expressed by NK cells, subsets of αß and γδ T cells, and invariant CD1d-specific Natural Killer T (NK-T) cells (80) (81) (82) . The KLRB1 receptor, by interacting with its ligand LLT1 (83, 84) , plays an inhibitory role in NK cellmediated cytotoxicity and IFNg secretion during immune responses to pathogens (80, (83) (84) (85) . Polymorphisms in KLRB1 are associated with structural alterations of the protein, and impact its regulatory functions on NK cell homeostasis and activation (86) . In contrast to its inhibitory potential in NK cells, the function of KLRB1 in T cells is less clear, with reports suggesting both co-activating (81, 85, 87) and inhibitory (88, 89) effects. CD161 (KLRB1) has been used as a marker to define Th17 and Tc17 subsets of CD4+ and CD8+ T cells that secrete the proinflammatory cytokine interleukin IL-17. However, a more recent study found that CD161-expressing T cell subsets are not all committed to the Th17 axis but are much more diverse, and that expression of CD161 identifies a transcriptional and functional phenotype shared across human T lymphocytes that is independent of both T cell receptor (TCR) expression and cell lineage (87) . The dysregulation of KLRB1 in SLE may be directly linked to aberrant IFNg signaling pathways and immune cell subpopulations in this disease.
GPR183 (also known as EBI2) encodes the G Protein-Coupled Receptor 183 that binds oxysterols, the most potent of which is 7α, 25-dihydroxycholesterol (7α,25-OHC) (90) . GPR183 is up-regulated in a Burkitt's lymphoma cell line upon Epstein-Barr virus infection (91) , an infection that is also strongly linked to SLE (91, 92). Interestingly, GPR183 is also strongly induced in UVB-irradiated skin biopsies (93) and UV light has been postulated to induce SLE photosensitivity (94) and DNA damage-driven apoptosis (95) . The GPR183 protein is a negative regulator of IFN (96) . In lymphoid organs, GPR183 plays a key role in mediating the migration and antibody response of multiple immune cell types including B cells, T cells, dendritic cells and monocytes (97) (98) (99) (100) (101) . GPR183-deficient mice have fewer plasma cells, reduced antibody titers (97, 98) , and diminished CD4+ splenic dendritic cells. In another study, mice lacking GPR183 or its 7α,25-OHC ligand show defects in the trafficking of group 3 innate lymphoid cells and defects in lymphoid tissue formation in the colon (102) . GPR183 has been implicated in inflammatory and autoimmune diseases, including multiple sclerosis (103), inflammatory bowel disease (104), Crohn's disease (104), type 1 diabetes, and cancer (101) . In multiple sclerosis, data from the experimental autoimmune encephalomyelitis (EAE) animal model suggest that GPR183 is a critical mediator of CNS autoimmunity and regulates the migration of autoreactive T cells into inflamed organs (105) . Thus, the intriguing links between GPR183 and SLE through Epstein-Barr virus, IFN, and UV-light, as well as its important functions in instructing immune cell localization and antibody response, identify GPR183 and its ligand 7α, 25-OHC as potential biomarkers and/or therapeutic targets for SLE.
Research in many immunological disorders, including SLE, has recently focused on the importance of immunometabolism in disease (106, 107) . In SLE, particular focus has been on T cell metabolism (mitochondria, oxidative stress, mTOR, glucose, and cholesterol pathways), with additional interest in B cells (glycolysis and pyruvate), macrophages (stress response), dendritic cells (mTOR, fatty acids), and neutrophils (NETosis, oxidation) (107) . Concordant with these prior findings, our pathway analysis (26) of the SLE MetaSignature recapitulated many similar immunometabolic pathways in SLE, including pyruvate metabolism, fructose galactose metabolism, and oxidative stress response. In addition, our pathway analysis identified many non-inflammatory pathways involved in nucleic acid metabolism (including formyltetrahydrofolate biosynthesis, salvage pyrimidine deoxyribonucleotides, salvage pyrimidine ribonucleotides, and purine metabolism). Two therapies in SLE, methotrexate (108) and leflunomide (109) (110) (111) , both inhibit nucleic acid metabolism (112) (113) (114) (115) , and other new molecular entities that target these pathways are entering clinical trials. Collectively, our pathway analysis results reinforce the importance of immunometabolic pathways in SLE pathogenesis.
Arguably, our approach, which leverages heterogeneity within patient populations to identify a common transcriptional signature across SLE, is ill-suited in the era of "personalized medicine". A goal of personalized medicine is to cluster heterogeneous patients into homogeneous subgroups, which does not account for the individual variations that should be targeted. The underlying assumption is that the individual variation between subgroups is likely causal, which can be targeted to improve therapy and outcomes. However, it is equally likely that the disease-causing biology may be the same across all patients, and the variation observed between patients and subgroups is a result of environmental exposures. Studying a homogeneous patient population may identify a signature that explains the variation between groups but may not be causal and therapeutically relevant. Therefore, we believe that a more suitable approach would be to complement "personalized medicine" with "precision medicine" in SLE such that it first provides a precise molecular definition of SLE, such as we have done here. This could then lead to identification of multiple drug targets and corresponding therapies, increasing the number of drugs available to treat SLE patients.
We anticipate that the full SLE Metasignature, and particularly the Under-appreciated SLE MetaSignature, will be tested in blood and tissue derived from prospectively collected SLE cohorts to identify relationships between SLE flares, clinical subgroups, and responses to newly-tested therapies. Another important question is whether the proteins encoded by these genes are abnormally expressed or observed in unanticipated cell populations or tissues. Our results will help guide targeted analyses of SLE blood and kidney samples using single cell technologies such as scRNA-Seq, ATAC-Seq, Cytometry Time of Flight, Multiplexed Ion Beam Imaging, and CO-Detection by IndEXing (116) . Many of these novel methods are being utilized by the Accelerating Medicines Partnership RA/SLE program to characterize human SLE tissue, with a goal to identify novel pathways and disease targets (117) . Ongoing studies using CRISPR screens and immunohistochemistry are interrogating the role played by these genes in cultured immune cells, as well as the effect of the Under-appreciated SLE MetaSignature on interferon signaling, neutrophil biology, and animal models.
Our analysis has a few limitations. First, we focused on identifying a gene signature that is conserved between cohorts and across samples, and does not identify patient subgroups. While this is beneficial for capturing features that are consistent across populations, it is ill-suited for identifying subgroups of disease. Second, because we only used publicly available datasets, our analyses were restricted to the comparisons available in the public data, including tissues, cell types, and diseases sampled. To enable even richer analysis, we encourage the research community to contribute richly annotated datasets to the public domain. In the context of SLE, particularly important annotations, when available, include: age, sex, SLEDAI with individual components specifically recorded, drugs at the time of blood draw, drug doses and start dates, organ system involvement, cell proportions from complete blood count or flow cytometry.
Recent studies have been dominated by important discoveries that link type I IFN, neutrophils, and NETs to SLE. We have identified a unified SLE MetaSignature that implicates 14 underappreciated genes in SLE pathogenesis, only four of which were identified through a direct PubMed search of SLE (KLRB1, GRN, CD1C, and ABCB1, with 2, 5, 7, and 9 references each, respectively). Scouring of published literature reveals connections to additional genes, including ELANE, EBI2, and LHFPL2, but none of these have garnered significant attention in SLE research. Eight of the Underappreciated SLE MetaSignature genes have plausible roles in SLE, because they are expressed in immune cells, skin, or stress response. Perhaps even more interesting are the six genes (ABCB1, GRN, LHFPL2, NAP1L3, TCN2, and VSIG1) that are not linked to the immune system, plausible pathogenic mechanisms, or autoimmune diseases. Scientists often fall prey to the "streetlight effect" -looking for answers where the light is better rather than where the truth is more likely to lie (118) (119) (120) (121) . While many of the Under-appreciated SLE MetaSignature genes "make mechanistic sense", we should not lose sight of the six genes which had previously been in the shadows but are now illuminated.
Methods
Study approval
The vast majority of the data was obtained from public repositories. For the prospective validation analysis, all subjects were recruited and all samples were collected following protocols approved by the Stanford University Institutional Review Board (IRB protocol #13952, 14734).
Additional methods
Due to space contraints, methods are available in Supplemental Methods.
Author contributions
Designing experiments: WAH, PJU, PK; Conducting experiments: DJH, VKD, IB; Acquiring data: WAH, EB, CRB; Analyzing data: WAH, DJH, EB, CRB; Acquiring samples: IB, PJU; Writing manuscript: WAH, DJH, AK, VKD, EB, GY, IB, CRB, RM, PJU, PK. We downloaded 40 publicly-available datasets from 17 centers in five countries comprising 7,471 samples. We identified datasets that included whole blood or PBMC samples from SLE patients and healthy volunteers to serve as discovery (6 studies) and validation (8 studies) sets. The remaining 26 studies contained samples from other tissue types or lacked healthy volunteer samples, and were examined as extended validation datasets. We used the MetaIntegrator framework to identify a 93 gene SLE MetaSignature (effect size > 1, FDR < .05, measured in ≥ 4 datasets). We examined the classification accuracy of the signature in validation data and the generalizability of the signature in the extended validation data. To prospectively validate the SLE meta-analysis signature using an external cohort, we analyzed individuals who have pSLE (n=43) or JIA (n=12) from the Stanford Pediatric Rheumatology Clinic, as well as healthy adult (n=10) volunteers using Fluidigm RT-qPCR arrays. (B) We leveraged publicly-available data to identify non-IFN components of the SLE MetaSignature, examine the role of neutrophils in SLE, and study heavy metal exposure. Figure 2 . SLE MetaSignature persists across diverse datasets. Effect size heatmaps of SLE MetaSignature genes across (A) discovery, (B) validation, and (C) extended validation datasets. Each column represents a gene in the SLE MetaSignature, ordered from lowest-to highest-effect size in the discovery data. Each row represents a gene expression dataset. Receiver operating characteristic curves are broken into (D) discovery and (E) validation data. A perfect classifier will have an AUROC of 1 and a random classifier will have an AUROC of 0.5. We show both whole blood (WB) and peripheral blood mononuclear cell (PBMCs) samples. The summary curve is a composite of the individual study curves. The extended validation ROC plot is shown in Figure S9 . Red indicates the 70 genes which were in the SLE MetaSignature and were significantly differentially expressed in response to IFN. Green indicates the 9 genes which were in the SLE MetaSignature, were not significantly differentially expressed in response to IFN, and were significantly differentially expressed in neutrophils. Blue indicates the 14 genes in the SLE MetaSignature that were not significantly differentially expressed in neutrophils or in response to IFN stimulation. Dashed lines indicate an effect size threshold of |0.8| for both neutrophil and IFN effect sizes. (B) Cell lines which were chronically exposed to cadmium displayed an increased Under-appreciated SLE MetaScore compared to control cell lines. (C) Cells exposed to a water soluble zinc compound exhibited an increased Under-appreciated SLE MetaScore compared to those exposed to both a control compound and an insoluble form of zinc (40) . For all panels, Mann-Whitney U p-values are shown for pairwise comparisons. 
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